Search 

Gene Therapy company delivering Intrabodies with AAV delivery targeting misfolded proteins in neurodegenerative diseases. INT41 for Huntington’s Disease is our flagship product with successful results in cell based and animal models for Huntington's disease with additional indications. INT41 has Orphan Designation from the FDA.

Our platform selects Intrabodies that target novel intracellular mutations or stabilize refolding and can be applied to multiple therapeutic areas. 

We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity.  We have the only drug that treats low bladder capacity, which is an issue for 76% of nocturia sufferers.  Our clinical trial results were 5x better than the first FDA approved nocturia drug and 2.5x better than the other FDA approved nocturia drug, both of which carry a black warning about a dangerous blood disorder and have other side effects.  Of course these drugs treat polyuria rather than low bladder capacity, so they are not competitors for our drug.

YDS Medicine, Inc. (referred to as “YDS”) provides computational drug discovery services. Through our proprietary self-learning AI drug discovery system, YDS is assisting pharma and biotech companies to reduce their drug discovery cost by at least 20% while doing it 10X faster and increasing success rate by at least 20%.

YDS is endeavoring to decrease the cost of drug discovery, especially in the lead discovery and optimization stages. To decrease such trial-and-error costs at these stages, YDS shifts the knowledge-based process to a self-learning process. The AI+biophysics system developed at YDS is able to optimize chemical molecules towards desired biophysical/chemical properties, serving as GPS for the drug discovery journey.

healthcare VC

Project assessment, auditing, project management, regulatory affairs, quality, and IP management services

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

干细胞